Silent carotid atherosclerosis in patients with coronary disease;Aterosclerosis subclínica de la arteria carótida en pacientes con enfermedad coronaria

Medicina Clinica

Volumn 116, Issue 12, 2001, Pages 441-445

  Fernández Miranda, Consuelo ^a   Aranda, José Luis ^a   Paz, Manuel ^a   Núñez, Victor ^a   González, Pilar Gómez ^a   Díaz Rubio, Pilar ^a   Larumbe, Sagrario ^a   Izquierdo, M Teresa Gómez ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

B mode ultrasonography; Carotid atherosclerosis; Coronary disease; Intima media thickness; LDL cholesterol; Smoking

Indexed keywords

AGED; ARTERIOSCLEROSIS; ARTICLE; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; ECHOGRAPHY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PREVALENCE; STATISTICAL MODEL;

AGED; ARTERIOSCLEROSIS; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; ULTRASONOGRAPHY;

EID: 0040154743     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)71864-7     Document Type: Article

References (36)

1. Persson J, Stavenow L, Wikstrand J, Israelsson B, Formgren J, Berglund G. Reproductibility of ultrasonographic measurement of arteriol wall thickness and plaque size. Arterioscler Thromb 1992; 12: 261-266.
2. Zambón D, Gilabert R, Ros E, Casals E, Sanllehy C, Rodríguez C et al. aterosclerosis carotides evaluada por ecografía bidimensional en pacientes con hipercolesterolemia primaria. Med Clin (Barc) 1995; 105: 761-767.
3. Grobbee DE, Bols ML. Carotid intima-media thickness as an indicator of generalized atherasclerosis. J Intern Med 1994; 236: 567-573.
4. Tell GS, Howard G, McKinney WM, Toole JF. Cigarette smoking cessation and extracranial carotid atherosclerosis. JAMA 1989; 261: 1178-1180.
5. O'Leary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG, Wolfson SK et al. Distribution and correlates of sonographically detected carotid artery disease in the cardiovascular health study. Stroke 1992; 234: 1752-1760.
6. Malinow MR, Nieto J, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993; 87: 1107-1113.
7. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87: (Supl 2): 56-65.
8. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kajimoto Y et al. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging. Diabetes 1994; 43: 634-639.
9. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW et al. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Stroke 1994; 25: 66-73.
10. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-291.
11. Arnett DK, Tyroler HA, Burke G, Hutchinson R, Howard G, Heiss G et al. Hypertension and subclinical carotid artery atherosclerosis in blacks and whites. The Atherosclerosis Risk in Communities Study. Arch Intern Med 1996; 156: 1983-1989.
12. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M. Carotid artery intima media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 1996; 27: 1986-1992.
13. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987-1993. Am J Epidemiol 1997; 146: 483-494.
14. Tonstad S, Joakimsen O, Stensland-Bugge E, Ose L, Bonaa KH, Leren TP. Carotid intima-media thickness and plaque in patients with familiar hypercholesterolemia mutations and control subjects. Eur J Clin Invest 1998; 28: 971-979.
15. Wittekoek ME, De Groot E, Prins MH, Trip MD, Buller HR, Kastelein JJ. Differences in intimamedia thickness in the carotid and femoral arteries in familiar hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis 1999; 146: 271-279.
16. Spence JD, Barnett PA, Bulman DE, Hegele RA. An approach to ascertain probands with a non-traditional risk factor for carotid atherosclerosis. Atherosclerosis 1999; 144: 429-434.
17. Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. Stroke 1995; 26: 386-391.
18. Beaudry M, Spence JD. Measurement of atherosclerosis: development of an atherosclerosis severity index. Clin Exp Hypertens 1989; A11: 943-956.
19. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE Common carotid intima-media thickness and risk of stroke and myocardial infarction. The Rotterdam study. Circulation 1997; 96: 1432-1437.
20. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for miocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.
21. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto J et al. Carotid wall thickness is predictive of incident clinical stroke. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2000; 151: 478-487
22. Hobbs HH, White AL. Lipoprotein (a): intrigues and irsights. Curr Opin Lipidol 1999; 10: 225-236.
23. Fernández-Miranda C, Aranda JL, Gómez González P, Diaz-Rubio P, Estenoz J, Gömez de la Cámara A, La hiperhomocisteinemia es frecuerte en pacientes con enfermedad coronaria. Estudio de 202 enfermos. Med Clin (Barc) 1999: 113: 407-410.
24. Jukema JW, Bruschke AVG, Van Bover AJ, Reiber JHC, Bal ET, Zwinderman AH et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-2540.
25. Herd JA, Ballantyne CM, Farmer JA Effects of fluvastatine on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCASI). Am J Cardiol 1997; 80: 278-286.
26. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio S et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the carotid atherosclerosis Italian ultra-sound study. Am J Med 1996; 101: 627-634.
27. McMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID atherosclerosis substudy. Circulation 1998; 97: 1784-1790.
28. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
29. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results fo AFCAPS/TexCAPS. JAMA 1998: 279: 1615-1622.
30. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
31. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients wth average cholesterol levels. N Engl J Med 1996; 335: 1001-1009
32. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 1998; 339: 1349-1357
33. Hebert PR, Gaziano JM, Chan KS, Hennekens CH Cholesterol lowering with statin drugs, risk ot stroke, and total mortality: an overview of randomized trials. JAMA 1997; 278: 313-321.
34. Warshafsky S, Packard D, Marks SJ, Sachdeva N, Terashita DM, Kaufman G et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med 1999; 14: 763-774
35. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JDG, Hunt D et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343: 317-326.
36. Hess DC, Demchuk AM, Brass LM, Yatsu FM. HMG-CoA reductase inhibitors (statins). A promising approach to stroke prevention. Neurology 2000; 54: 790-796.